REFERRAL CRITERIA AND CLINICAL APPLICATION OF PREVENTIVE BRCA1/BRCA2 GENETIC TESTING IN BREAST AND OVARIAN CANCER: A NARRATIVE REVIEW
DOI:
https://doi.org/10.31435/ijitss.4(52).2026.6842Keywords:
BRCA1, BRCA2, Hereditary Breast And Ovarian Cancer (HBOC), Next-Generation Sequencing (NGS), PARP Inhibitors, Prophylactic Salpingo-Oophorectomy, Risk-Reducing Mastectomy, Cascade TestingAbstract
Background: Patients inheriting BRCA1 or BRCA2 mutations face significantly elevated risks of breast, ovarian, and pancreatic cancers, and melanoma. Identifying high-risk individuals enables timely prevention and selection of targeted therapies.
Objectives: This review summarizes genetic testing referral guidelines, discusses BRCA1/2 roles in DNA repair, presents modern diagnostic methods, and addresses preventive strategies for mutation carriers.
Methods/Scope: A comprehensive examination of clinical practice guidelines (including NCCN criteria), diagnostic paradigms (NGS, MLPA, Sanger sequencing), risk assessment models, targeted therapies, surgical risk-reduction strategies, and lifestyle factors was conducted.
Results/Discussion: Genetic testing enables early carrier identification for prevention and qualifies cancer patients for targeted PARP inhibitor therapy. Next-Generation Sequencing (NGS) has replaced Real-time PCR—which only detected common founder mutations—achieving diagnostic sensitivity above 99%. Qualification relies on pedigree analysis and risk evaluation. Prophylactic bilateral mastectomy and salpingo-oophorectomy reduce breast and gynecological cancer risks by 90–95%, while intensified surveillance with MRI ensures early detection. Young BRCA1/2 carriers face challenges regarding fertility preservation, surgical menopause, altered body image, and psychological stress, requiring multi-specialty care. Male carriers also require structured prostate and breast monitoring.
Conclusion: Early identification of BRCA1/2 carriers by primary care physicians, gynecologists, and oncologists is essential for optimizing risk reduction, surveillance, and personalized oncology. Population-wide screening in individuals with unburdened family histories remains unindicated.
References
Petrucelli, N., Daly, M. B., & Pal, T. (1998, September 4; updated March 25, 2026). BRCA1- and BRCA2-associated hereditary breast and ovarian cancer. In M. P. Adam, S. Bick, G. M. Mirzaa, et al. (Eds.), GeneReviews® [Internet] (1993–2026). University of Washington, Seattle. https://www.ncbi.nlm.nih.gov/books/NBK1247/
Sessa, C., Balmaña, J., Bober, S. L., Cardoso, M. J., Colombo, N., Curigliano, G., et al. (2023). Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO clinical practice guideline. Ann Oncol, 34(1), 33–47.
Committee on Practice Bulletins-Gynecology, Committee on Genetics, & Society of Gynecologic Oncology. (2017). ACOG practice bulletin no. 182: Hereditary breast and ovarian cancer syndrome [Reaffirmed 2024]. Obstet Gynecol, 130(3), e110–e126. https://doi.org/10.1097/AOG.0000000000002296
Obwieszczenie Ministra Zdrowia z dnia 6 września 2024 r. w sprawie kluczowych zaleceń w zakresie opieki onkologicznej dotyczących organizacji i postępowania klinicznego w raku piersi. (2024). Dziennik Urzędowy Ministra Zdrowia, poz. 71. https://dziennikmz.mz.gov.pl/DUM_MZ/2024/71/oryginal/akt.pdf
National Comprehensive Cancer Network. (2026). NCCN guidelines for Poland: Invasive breast cancer (comprehensive version 3.2026). https://www.nccn.org/guidelines/category_1
National Comprehensive Cancer Network. (2026). NCCN clinical practice guidelines in oncology: Breast cancer (version 9.2026). https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
Tysarowski, A., Szumera-Ciećkiewicz, A., Marszałek, A., Kowalik, A., Seliga, K., Bidziński, M., et al. (2023). Molecular diagnostics of cancers practical approach. NOWOTWORY J Oncol, 73(3), 174–186. https://doi.org/10.5603/NJO.2023.0028
Jassem, J., Krzakowski, M., Bobek-Billewicz, B., Duchnowska, R., Jeziorski, A., Olszewski, W., et al. (2018). Breast cancer. Oncol Clin Pract, 14(4), 187–210. https://doi.org/10.5603/OCP.2018.0027
National Cancer Institute. (2020). BRCA gene mutations: Cancer risk and genetic testing [Internet]. Retrieved October 26, 2026, from https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet
Centers for Disease Control and Prevention. (2023). Cascade testing for hereditary breast and ovarian cancer [Internet]. Retrieved October 26, 2026, from https://www.cdc.gov/genomics/disease/breast_ovarian_cancer/cascade_testing.htm
Daly, M. B., Pal, T., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., et al. (2021). Genetic/familial high-risk assessment: Breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 19(1), 77–102. https://doi.org/10.6004/jnccn.2021.0001
Wielgoś, M., Krzakowski, M., Czajkowski, K., Giermek, J., Jagiełło-Gruszfeld, A., Wojciechowska-Lampka, E., et al. (2016). Standardy postępowania w przypadkach choroby nowotworowej u kobiety w ciąży. Część I. Wiadomości ogólne: Epidemiologia, diagnostyka, leczenie, poradnictwo genetyczne. Ginekol Perinatol Pract. https://share.google/rwXdv7AZJb8gEkXRu
Kushi, L. H., Doyle, C., McCullough, M., Rock, C. L., Demark-Wahnefried, W., Bandera, E. V., et al. (2012). American cancer society guidelines on nutrition and physical activity for cancer prevention: Reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin, 62(1), 30–67. https://doi.org/10.3322/caac.20140
Cheng, H. H., Giri, V. N., Goggins, M., Yurgelun, M. B., Karlan, B. Y., Norquist, B. S., et al. (2026). NCCN guidelines insights: Genetic/familial high-risk assessment: Breast, ovarian, pancreatic, and prostate, version 2.2026. J Natl Compr Canc Netw, 24(2), 2–10. https://doi.org/10.6004/jnccn.2026.0007
Roy, R., Chun, J., Powell, S. N. (2011). BRCA1 and BRCA2: Different roles in a common pathway of genome protection. Nat Rev Cancer, 12(1), 68–78. https://doi.org/10.1038/nrc3181
Lord, C. J., Ashworth, A. (2017). PARP inhibitors: Synthetic lethality in the clinic. Science, 355(6330), 1152–1158. https://doi.org/10.1126/science.amc1080
Robson, M., Im, S. A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., et al. (2017). Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med, 377(6), 523–533. https://doi.org/10.1056/NEJMoa1706450
Tutt, A. N. J., Garber, J. E., Kaufman, B., Viale, G., Fumagalli, D., Rastogi, P., et al. (2021). Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med, 384(25), 2394–2405. https://doi.org/10.1056/NEJMoa2105215
Medycyna Praktyczna. (2017). Pacjenci z grupy dużego dziedzicznego ryzyka zachorowania na raka piersi i raka jajnika (w tym nowotwory BRCA-zależne) – badania, opieka i profilaktyka [Internet]. Retrieved October 26, 2026, from https://www.mp.pl/ginekologia/ginekologia-onkologiczna/155053
Zwrotnik Raka. (2023). Mutacje genów BRCA1 i BRCA2 – dziedziczny rak piersi i rak jajnika [Internet]. Retrieved October 26, 2026, from https://www.zwrotnikraka.pl/mutacje-genow-brca1-i-brca2-dziedziczny-rak-piersi-i-rak-jajnika/
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Kinga Janiszek, Liwia Iwaniec, Wiktoria Jabłońska, Michał Uchański, Iga Januszaniec, Aleksander Mróz, Alicja Bonder, Michał Kiszka, Julia Janicka, Jolanta Janasik

This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.

